The PROTAC therapeutic market is forecast to grow significantly from 2025 to 2034, driven by increasing interest in targeted protein degradation as a next‑generation drug modality, and led by firms such as Arvinas. The analysis highlights expanding oncology pipelines and rising applicability in other disease areas as factors supporting sustained research and development investment.
PROTACs (Proteolysis Targeting Chimeras) represent a novel class of molecules that harness the cell’s ubiquitin‑proteasome system to selectively degrade disease‑causing proteins. 90 protein‑degradation leads are in development, with close to 20 percent in clinical stages and more in preclinical or discovery phases.
Key therapeutic candidates in the clinical pipeline include vepdegestrant, luxdegalutamide and others being evaluated by companies such as Arvinas in collaboration with Pfizer and Novartis, Astellas Pharma, and Dialectic Therapeutics. These candidates span indications in oncology and potentially neurodegenerative and inflammatory diseases.
The PROTAC market is segmented across major regions including the United States, EU4, the United Kingdom and Japan, and ties growth projections to the total addressable patient populations in conditions such as HR+/HER2‑ breast cancer, metastatic prostate cancer, colorectal cancer and non‑small cell lung cancer.
Overall, the PROTAC market’s accelerated growth reflects broader industry shifts toward therapies that go beyond traditional inhibition by eliminating target proteins, and it underscores significant investment interest in protein‑degradation technologies as potential future treatment options for unmet clinical needs.
